Truist raised the firm’s price target on Iovance Biotherapeutics to $26 from $17 and keeps a Buy rating on the shares. The firm is positive on the company’s strong initial demand signals for AMTAGVI, better pricing for the TIL – or tumor infiltrating lymphocyte – therapy as well as Proleukin, and resolution of the LUN-202 clinical hold, the analyst tells investors in a research note. A large majority of the value in Iovance price target is placed on the opportunity in melanoma and cervical cancer, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IOVA:
- Iovance Biotherapeutics: FDA lifts partial clinical hold on IOV-LUN-202 trial
- Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
- Iovance Biotherapeutics to Present at Upcoming Conferences
- Iovance Biotherapeutics price target raised to $25 from $22 at Wells Fargo
- Iovance Biotherapeutics price target raised to $22 from $18 at Barclays
